welcome
CNBC

CNBC

Health

Health

Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years

CNBC
Summary
Nutrition label

77% Informative

Novo Nordisk says its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial.

The pill lowered the risk of cardiovascular-related death, heart attack and stroke by 14% compared to a placebo.

The Danish drugmaker presented the results at the American College of Cardiology's Annual Scientific Session in Chicago .

The data suggests that patients who are hesitant to take injections, such as those who are afraid of needles, could soon access treatment in a more convenient way.

Small business owner?

Otherweb launches Autoblogger—a revolutionary way to bring more leads to any small business, using the power of AI.